<DOC>
	<DOCNO>NCT03089333</DOCNO>
	<brief_summary>New strategy try achieve blood pressure control consequently reduce cardiovascular risk resistant hypertensive subject promise . In context , SGLT2 inhibitor dapagliflozin , yet investigate resistant hypertension , arise potential drug order impact blood pressure level , well target organ damage adiposity high-risk population .</brief_summary>
	<brief_title>Effects SGLT2 Inhibitor Hemodynamic Parameters Resistant Hypertensive Subjects</brief_title>
	<detailed_description>Objective : The investigator aim ass whether intervention SGLT2 inhibitor -dapaglifozin - reduces PA level , target organ damage , fat profile change adipokines level patient resistant hypertension DM2 . Methods design : This crossover randomize , double-blind , interventional study control standard therapy include 20 patient resistant hypertension type 2 diabetes , follow Outpatient Clinic specialize Resistant Hypertension clinical Hospital-UNICAMP . They randomly assign two group ( 1 ) initially treat dapagliflozin combination usual antihypertensive therapy metformin , 12 week ( n = 10 ) group ( 2 ) Control initially treat glibenclamide dose 5mg daily combination antihypertensive therapy usual metformin , 12 week ( n = 10 ) . Office ambulatory home BP measurement ; anthropometric measurement , determination vascular stiffness pulse wave velocity , echocardiogram , body bioimpedance , enzyme immunoassays determination adipokines , lab test evaluate biochemical parameter perform pre- use treatment . Glycemic parameter , weight assess every 4 week . Results conclusion : The use SGLT2 inhibitor patient may provide new strategy treatment patient resistant hypertension .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomegaly</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Resistant hypertension type 2 diabetes diagnosis 6month followup Use metformin therapy Therapy adherence Agree participate research protocol sign inform consent form secondary Hypertension pseudoresistance hypertension ( poor medication adherence white coat hypertension ) patient symptomatic ischemic heart disease , impaired renal function , liver disease history stroke , myocardial infarction peripheral vascular disease pregnancy smoke autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>